20 July 2023
20 July 2023
Pfizer’s $25m investment is to support CellCentric’s CCS1477 to treat refractory and relapsed multiple myeloma.
Additional clinical data showed improved clinical and anatomical outcomes in DME and wet AMD.
Three out of five patients in the 6mg/kg bexmarilimab and azacitidine doublet cohort showed complete remission of bone marrow blasts.
CoronaTcP demonstrated a favourable safety profile and did not cause any serious adverse events in the trial.
The trial was enabled by the Kids Advanced Therapeutics Program at SCHN.
EG 427 plans to file for IND early next year to investigate EG110A in a Phase Ib/IIa trial with patients with neurogenic bladder due to spinal cord injury.
The company plans to conduct several other trials of NBTXR3, including a Phase II study in patients with recurrent or metastatic head and neck cancer.
Topline data from the study are expected by the end of this year.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
